8-K
Immunome Inc. (IMNM)
8-K
2023-01-30
For: 2023-01-30
View Original
Added on
April 12, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):January 30, 2023
Immunome, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39580 | 77-0694340 |
|---|---|---|
| (state or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 665 Stockton Drive, Suite 300 Exton, Pennsylvania | 19341 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (610) 321-3700
Not applicable
(Formername or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange<br> on which registered |
|---|---|---|
| Common Stock, $0.0001 par value per share | IMNM | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events. |
|---|
On January 30, 2023, Immunome, Inc. (the “Company”) posted a presentation to its website that may be used by the Company from time to time in meetings with investors, analysts, collaborators, vendors or other third parties. A copy of the presentation is attached as Exhibit 99.1 to this report and incorporated into this Item 8.01 by reference.
The information disclosed under this Item 8.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
|---|
(d) Exhibits.
| Exhibit<br><br> No. | Description |
|---|---|
| 99.1 | Presentation dated January 2023. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMMUNOME, INC. | |
|---|---|
| By: | /s/ Purnanand D. Sarma |
| Purnanand D. Sarma, Ph.D. | |
| President and Chief Executive Officer |
Dated: January 30, 2023
Exhibit 99.1
| Harnessing the Power<br>of the Human Memory<br>B Cell<br>JANUARY 2023<br>Immunome, Inc.<br>665 Stockton Drive, Suite 300 | Exton, PA<br>19341<br>610.321.3700 | <br>immunome.com<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved. |
|---|---|---|
| 2<br>Disclaimers and Forward<br>-<br>Looking Statements<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>This presentation includes certain disclosures that contain “forward<br>-<br>looking statements”<br>intended to qualify for the “safe harbor” from liability established by the Private Securities<br>Litigation Reform Act of 1995, as amended, including, without limitation, express or implied<br>statements regarding our beliefs and expectations regarding the advancement of our<br>oncology and infectious disease programs and platform, execution of our regulatory, clinical<br>and strategic plans, therapeutic potential and benefits of our programs and anticipated<br>upcoming milestones for our programs, as well as the timing and progress of each of the<br>foregoing matters. Forward<br>-<br>looking statements may be identified by the words “anticipate,”<br>believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “suggest,” “may,” “will,” “could,”<br> “should,” “seek,” “potential” and similar expressions. Forward<br>-<br>looking statements are based<br>on our current expectations and are subject to inherent uncertainties, risks and assumptions<br>that are difficult to predict. Factors that could cause actual results to differ include, but are<br>not limited to, the following: our ability to execute on our strategy, including with respect to<br>R&D efforts, IND submissions and other regulatory filings, timing of these filings and the<br>timing and nature of governmental authority feedback regarding the same, initiation and<br>completion of any clinical studies, confirmatory testing and other anticipated milestones as<br>and when anticipated; the fact that research and development data are subject to differing<br>interpretations and assessments, including during the peer review/publication process in the<br>scientific community and by regulatory authorities; whether our data will be published in a<br>scientific journal and, if so, when and with what modifications; the effectiveness of our<br>product candidates, including the possibility that further preclinical data and any clinical trial<br>data may be inconsistent with earlier<br>-<br>published data and/or data used for advancing the<br>product candidates; the fact that changes in the profile of the diseases that our programs<br>target could emerge that could impact our ability to address those changes; our ability to fund<br>operations; our reliance on vendors; our ability to execute on our plans for collaborations and<br>partnerships; the competitive landscape; the impact of the COVID<br>-<br>19 pandemic on our<br>business, operations, strategy, goals and anticipated milestones; and the additional risks and<br>uncertainties set forth more fully under the caption “Risk Factors” in Immunome’s Annual<br>Report on Form 10<br>-<br>K filed with the United States Securities and Exchange Commission (SEC)<br>on March 28, 2022, and elsewhere in Immunome’s Quarterly Reports on form 10<br>-<br>Q and other<br>filings and reports with the SEC.<br>All statements contained in this presentation are made as of the date specified on the cover,<br>and we undertake no duty to publicly update or revise any such statements, whether as a<br>result of new information, future events or otherwise, except as may be required under<br>applicable law.<br>This presentation may contain product names, trade names, trademarks and service marks of<br>Immunome and of other organizations, which are the properties of their respective owners.<br>Statements that “we believe” and similar statements reflect our beliefs and opinions on the<br>relevant subject. These statements are based on information available to us as of the date of<br>this presentation, including independent market research, industry publications and surveys,<br>governmental agency publications and other publicly available information. While we believe<br>that information provides a reasonable basis for these statements, it may be limited or<br>incomplete and we may have not independently verified it. Our statements should not be read<br>to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all<br>relevant information.<br>We make statements and predictions about future dates for achievement of milestones<br>related to our platform and our programs in this presentation. These statements and<br>predictions involve risks and uncertainties based on various factors and evolution over time<br>and, therefore, actual dates for these milestones may differ.<br>In this presentation and oral commentary, we may discuss our current and potential future<br>product candidates that have not yet undergone clinical trials or been approved for marketing<br>by the U.S. Food and Drug Administration or other governmental authority. No representation<br>is made as to the safety or effectiveness of these current or potential future product<br>candidates for the use for which such product candidates are being studied. This<br>presentation does not constitute an offering of securities of any kind. | ||
| --- | ||
| Powered by Human Memory B Cell<br>Interrogation<br>3<br>Immunome: Three<br>-<br>Pronged Strategy<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Successfully execute on AbbVie<br>collaboration<br> →<br>$30M upfront<br> →<br>Eligible for up to:<br> –<br>$70M platform access payments<br> –<br>Per target option payments (low<br>single digit millions)<br> –<br>$2.7B downstream economics<br> –<br>Tiered royalties<br>Extract value from the breadth of<br>Immunome’s Discovery Engine<br> →<br>Platform and asset<br>-<br>based<br>partnerships<br> →<br>Novel oncology target/antibody<br>pairs<br> –<br>Includes ADC, TCE modalities<br>Advance proprietary oncology<br>pipeline<br> →<br>IMM<br>-<br>ONC<br>-<br>01 (targeting IL<br>-<br>38)<br>IND submission by mid<br>-<br>2023<br> →<br>Research pipeline<br>03<br>02<br>01<br>Cash runway at least through 3Q 2024 | ||
| --- | ||
| 4<br>Strategic Discovery Collaboration with AbbVie<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br> →<br>AbbVie option to purchase worldwide rights for up to<br>10<br>novel target<br>-<br>antibody pairs<br>arising from<br>three<br>specified<br>tumor types<br> →<br>Key Financial<br>Terms<br> –<br>$30M<br>upfront payment<br> –<br>Eligible for additional payments up to:<br> •<br>$70M platform access payments (in addition to potential per<br>target<br>option payments<br> –<br>low single digit millions<br>)<br> •<br>$120M per target development and first commercial sale<br>milestones<br> •<br>$150M per target further sales<br>-<br>based milestones<br> •<br>Tiered royalties on global sales<br>This collaboration with AbbVie, a true leader in the<br>development and commercialization of oncology<br>therapeutics, demonstrates the strength of Immunome’s<br>Discovery Engine.<br>PURNANAND SARMA<br>President & CEO, Immunome<br>Immunome’s approach has the potential to unlock novel<br>cancer biology and yield multiple therapeutic candidates.<br>STEVE DAVIDSEN<br>VP, Oncology Discovery Research, AbbVie | ||
| --- | ||
| We See the Disease Through the Lens of a Memory B Cell<br>Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale<br>5<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Patient Ab responses<br>point to<br>actionable<br>public targets<br>2<br>03<br>Patient responses unveil novel disease targets<br>Proprietary Discovery<br>Engine<br>interrogates<br>function<br>of patient<br>memory B cell responses<br>02<br>Patients’ immune<br>responses<br>recognize and<br>respond<br>to disease in<br>clinically important ways<br>1<br>01<br>Immune<br>Modulation<br>Novel<br>Targets<br>Discovery<br>Engine<br>Extracellular<br>Matrix<br>1.<br>Nature<br>577<br>:549<br>-<br>555, 556<br>-<br>560, & 561<br>-<br>65 (2020)<br>2.<br>Immunome internal data<br>Cataloging the Context<br>-<br>Dependent<br>B Cell Response Against Cancer<br>We See the Disease Through the<br>Lens of a Memory B Cell<br>Broad Applicability Across<br>Therapeutic Areas | ||
| --- | ||
| Broad Applicability Across Therapeutic Areas<br>Unbiased Interrogation Unveils Targets & Underexplored Biology: Examples<br>6<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Immunology:<br>Conserved Epitopes<br>Identification of antibodies specific<br>for broadly conserved epitopes,<br>including across species<br>Infectious Disease:<br>Multi<br>-<br>modal Action<br>Unique insights into breadth<br>of immune response against SARS<br>-<br>CoV<br>-<br>2 by super responder patients<br>Oncology:<br>Target Rich Clusters<br>Targets identified across<br>patients<br>with different tumors cluster<br>around distinct areas of tumor<br>biology<br>Immune<br>Modulation<br>Novel<br>Targets<br>Discovery<br>Engine<br>Extracellular<br>Matrix<br>DiMuzio<br>et al<br>VaccineX<br>2021<br>Need a figure for<br>this panel<br>Knowles et al Nature Reviews Molecular Cell Biology (2014)<br>https://<br>doi.org<br>/10.1038/nrm3810 | ||
| --- | ||
| 7<br>Platform has Potential for Partnering<br>Across Therapeutic Areas<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br> →<br>$30M Upfront<br> →<br>$70M Platform<br>Milestones<br> →<br>Low single digit millions options<br>payments per target<br> →<br>$120M/target Development and First<br>Commercial Sale Milestones<br> →<br>$150M/target Sales based Milestones<br> →<br>Tiered Royalties on Global Sales<br>IMM<br>-<br>BCP<br>-<br>01<br>(SARS<br>-<br>CoV<br>-<br>2 Antibody Cocktail)<br>Anti<br>-<br>Infectives<br>01<br>Oncology<br>Solid Tumors<br>02<br>03<br>04<br>05<br> →<br>$17.6M<br>non<br>-<br>dilutive funding<br>(OTA: W911Q<br>-<br>Y<br>-<br>20<br>-<br>9<br>-<br>0019)<br> →<br>Funded by U.S. DoD JPEO<br>-<br>CBRND<br>in collaboration with DHA<br> →<br>Various Malignancies<br>Oncology, Hematology<br> →<br>Auto<br>-<br>Immune Disorders<br> →<br>Immunology<br>Immune Disorders<br> →<br>Neuroinflammation<br>Neurology<br>Up to 10 novel antibody<br>-<br>target<br>pairs in 3 tumor types<br>Potential Future Therapeutic Areas | ||
| --- | ||
| Immunome Pipeline<br>Targets Identified from Authentic Human Immune Response<br>8<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>PROGRAM<br>POTENTIAL DISEASE<br>OF RELEVANCE<br>STAGE<br>NEXT MILESTONE<br>IMM<br>-<br>ONC<br>-<br>01 (Anti<br>-<br>IL<br>-<br>38)<br>Soluble Cytokine, Immune Modulator<br>Neutralize IL<br>-<br>38; recruit and activate immune cells<br>Squamous carcinomas of<br>head & neck,<br>gastroesophageal, lung<br>Preclinical<br>Development<br>IND submission<br>mid<br>-<br>2023<br>IMM20059 (Anti<br>-<br>EPN1)<br>Membrane Dynamics<br>Ectopically expressed on cancer cells and exosomes; modulate<br>receptor trafficking; reactivate exhausted anti<br>-<br>tumor<br>T cells<br>Melanoma, breast, lung,<br>bladder, genitourinary, and<br>liver cancers<br>Target Research<br> & Lead ID<br>Lead nomination<br>Undisclosed oncology targets<br>Suitable for ADC and T Cell Engager Modalities<br>Solid tumors<br>Target Research<br> & Lead ID<br>Lead nomination<br>IMM<br>-<br>BCP<br>-<br>01 (Anti SARS<br>-<br>CoV<br>-<br>2)*<br>Three antibody cocktail (multi<br>-<br>modal action, including<br>neutralization and complement activation)<br>COVID<br>-<br>19<br>Phase 1b*<br>Actively exploring<br>partnerships<br>OTHER<br>ONCOLOGY<br> •<br>We completed dosing of the first cohort of patients<br>with no significant treatment<br>-<br>related adverse events. We have decided to see<br>k a partner in order to continue the trial and for any<br>further development activities. | ||
| --- | ||
| ONCOLOGY<br>Platform and Pipeline<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved. | ||
| --- | ||
| B cells: Critical Players in Immunity<br>Oncology<br>10<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br> →<br>B cell infiltration more closely associated with<br>survival than T cell presence in multiple cancers<br> →<br>Success of I/O therapies appears to be<br>associated with coordinated response including<br>B cells and TLS in the unique context of each<br>patient’s tumor microenvironment<br> →<br>However, specificity of the B cell immune<br>repertoire<br>has not been explored<br>beyond known<br>tumor antigens<br>Cabrita<br>et al, Nature (2020)<br>Survival in Melanoma Patients | ||
| --- | ||
| Immunome’s Discovery Engine<br>Functional B Cell Interrogation to Actionable Public Targets<br>11<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Functional screening<br>prioritizes patient<br>-<br>derived<br>antibodies that bind to<br>actionable public targets<br>0<br>..<br>0<br>1<br>0<br>..<br>1<br>1<br>1<br>0<br>1<br>0<br>0<br>0<br>20<br>40<br>60<br>80<br>100<br>Log Conc. (nM)<br>%<br><br>C<br>y<br>t<br>o<br>t<br>o<br>x<br>i<br>c<br>i<br>t<br>y<br>Antibody B -Vc-MMAF<br>anti-RSV<br>-Vc-MMAF<br>Unconj. Vc-MMAF<br>Cetuximab-Vc-MMAF<br>Tr<br>a<br>s<br>t<br>u<br>z<br>u<br>m<br>a<br>b<br><br>(<br>H<br>e<br>r<br>2<br>)<br>03<br>Memory B Cells Represent One of the Most Educated Components of the Human Immune System<br>Discovery Engine<br>interrogates patient<br>memory B cell responses<br>in<br>unbiased manner and<br>at industrial scale<br>02<br>Tumor Types<br>B cells identify important<br>targets within the natural<br>context of disease<br>01<br>Pero et al,<br>Clin Trans Immunol<br>(2022)<br>Autologous Tumor binding<br>Immunome Internal Data | ||
| --- | ||
| Unveiling “Tumor Context”<br>Novel Insights Into<br>Tumor<br>Targets and Biological Processes<br>12<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Immune<br>Modulation<br>Novel<br>Targets<br>Discovery<br>Engine<br>Extracellular<br>Matrix<br>Platform<br>identifies both validated and novel actionable<br>cancer targets<br>Identifies targets with expression linked to clinical<br>outcomes (IMM<br>-<br>ONC<br>-<br>01 targeting IL<br>-<br>38)<br>Discovery Engine highlights unique features<br>of cancer cells<br> →<br>Unexpected localization of proteins<br>(<br>ectopic expression<br>)<br>on<br>tumor surface<br>~250K<br>HYBRIDOMAS<br> >70<br>ANTIBODY /<br>TARGET PAIR<br>14<br>CANCERS<br> >350<br>PATIENTS<br>Diverse Cancer Landscape<br>Antibody responses across diverse cancers<br>highlight common<br>areas of target<br>-<br>rich biology | ||
| --- | ||
| Ectopic Expression: A Unique Class<br>of<br>Targets with Potentially High Tumor Selectivity<br>High Throughput Identification of Antibody<br>-<br>Target Pairs for Novel Modalities<br>13<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Highly Productive Discovery Engine for ADC and TCE Targets<br>High Throughput Functional Characterization:<br>Example of a Typical Cascade<br>Strong binding to tumor<br>No binding to normal<br>Internalization<br>5 T Cell Engager (TCE)<br>mAbs<br>(16%)<br>Binds tumor cells<br>Does not bind normal cells<br>No internalization<br>5 ADC<br>mAbs<br>(16%)<br>Binds tumor cells<br>Does not bind normal cells<br>Efficient internalization<br>32 Antibodies<br>Ectopic Expression<br>Ectopically Expressed Targets:<br>Some proteins normally found intracellularly appear to<br>be selectively expressed on surface of tumor cells<br>02<br>01 | ||
| --- | ||
| Example of an Ectopically Expressed<br>Target as an ADC<br>14<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>*Immunome internal data<br>0<br>1<br>0<br>0<br>0<br>2<br>0<br>0<br>0<br>3<br>0<br>0<br>0<br>4<br>0<br>0<br>0<br>0<br>10<br>20<br>30<br>40<br>Raw Binding Signal<br>S<br>-<br>S<br>c<br>o<br>r<br>e<br>17. PR121-00372<br>C1<br>1orf68<br>Target B<br>Ab Highly Selective for<br>Single Protein Target<br>Selective Tumor Cell<br>Binding<br>High<br>Tumor:Normal<br>Cell<br>Binding Ratio<br>Tumor<br>Normal<br>0<br>..<br>0<br>1<br>0<br>..<br>1<br>1<br>1<br>0<br>1<br>0<br>0<br>0<br>20<br>40<br>60<br>80<br>100<br>Log Conc. (nM)<br>%<br><br>C<br>y<br>t<br>o<br>t<br>o<br>x<br>i<br>c<br>i<br>t<br>y<br>Anti-C1<br>1orf68-VC-MMAF<br>Cetuximab-VC-MMAF<br>Tr<br>a<br>s<br>t<br>u<br>z<br>u<br>m<br>a<br>b<br>-<br>V<br>C<br>-<br>M<br>M<br>A<br>F<br>anti-RSV<br>-VC-MMAF<br>free MMAF<br>0<br>..<br>0<br>1<br>0<br>..<br>1<br>1<br>1<br>0<br>1<br>0<br>0<br>0<br>20<br>40<br>60<br>80<br>100<br>Log Conc. (nM)<br>%<br><br>C<br>y<br>t<br>o<br>t<br>o<br>x<br>i<br>c<br>i<br>t<br>y<br>Antibody B -Vc-MMAF<br>anti-RSV<br>-Vc-MMAF<br>Unconj. Vc-MMAF<br>Cetuximab-Vc-MMAF<br>Tr<br>a<br>s<br>t<br>u<br>z<br>u<br>m<br>a<br>b<br><br>(<br>H<br>e<br>r<br>2<br>)<br>Free MMAF<br>Anti<br>-<br>RSV<br>-<br>VC<br>-<br>MMAF<br>Antibody B<br>-<br>VC<br>-<br>MMAF<br>Cetuximab (EGFR)<br>-<br>VC<br>-<br>MMAF<br>Trastuzumab (Her2)<br>-<br>VC<br>-<br>MMAF<br>Internalization<br>Patient<br>-<br>derived Ab Suitable<br>for ADC Format<br>0<br>6<br>12<br>18<br>24<br>0.0<br>5<br>..<br>0<br> ×<br>1<br>0<br>4<br>1<br>..<br>0<br> ×<br>1<br>0<br>5<br>1<br>..<br>5<br> ×<br>1<br>0<br>5<br>Ti<br>m<br>e<br><br>(<br>h<br>)<br>R<br>e<br>d<br><br>t<br>o<br>t<br>a<br>l<br><br>i<br>n<br>t<br>e<br>g<br>r<br>a<br>t<br>e<br>d<br><br>i<br>n<br>t<br>e<br>n<br>s<br>i<br>t<br>y<br>/<br>P<br>h<br>a<br>s<br>e<br><br>A<br>r<br>e<br>a<br>Anti-C1<br>1orf68<br>a-RSV<br>Neg<br>Cntrl<br>Antibody B<br>01 | ||
| --- | ||
| Recent Clinical Success and<br>Approvals Fueling Significant<br>Investment in the ADC Space<br>ADC Market: New Targets and<br>Technologies Likely to Accelerate Growth<br>Significant Number Of Recent ADC Approvals<br>15<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>1.<br>The Antibody Society. Therapeutic monoclonal antibodies approved or in regulatory review. January 14, 2023;<br>www.antibodysociety.org/antibody<br>-<br>therapeutics<br>-<br>product<br>-<br>data<br>..<br> | <br>2. www.cortellis.com<br> | <br>3. www.clinicaltrials.gov<br>Robust Deal Activity in Linker/Payload Technologies<br> →<br>2020<br>-<br>2023<br> →<br> >10 deals in the range $400M<br>-<br>$2.6B<br>2<br>Clinical Landscape<br>2,3<br> →<br> >10 active Late Clinical Programs<br>2<br> →<br> >130 active Early Clinical Programs<br>2<br> →<br> >250 ongoing clinical studies<br>3<br>4. Image<br>adapted<br>from: Fu, Z., Li, S., Han, S.<br>et al.<br>Antibody drug conjugate: the “biological missile” for targeted cancer ther<br>apy.<br>Sig<br>Transduct<br>Target<br>Ther<br>7, 93 (2022).<br>https://doi.org/10.1038/s41392<br>-<br>022<br>-<br>00947<br>-<br>7<br>4<br>1 |
| --- | ||
| 16<br>Novel Targets Could Drive Future ADC Market Growth<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Differentiated IMNM<br>Platform<br> →<br>High throughput identification of novel targets<br> →<br>Ectopically expressed<br>Commercial/Phase 3 Solid Tumor ADC Programs are Still Mostly<br>Directed at a Limited Number of Known<br>Targets<br>1,2<br>TOMORROW<br>TODAY<br>TROP2<br>FolR1<br>HER2<br>cMet<br>Nectin4<br>CECAM5<br>ROR1<br>NaPi2b<br>HER3<br>TF<br>1.<br>The Antibody Society. Therapeutic monoclonal antibodies approved or in regulatory review. January 14, 2023;<br>www.antibodysociety.org/antibody<br>-<br>therapeutics<br>-<br>product<br>-<br>data<br>..<br> | <br>2.<br>The Antibody Society.<br>Antibody therapeutics in late<br>-<br>stage clinical studies. January 14, 2023;<br>www.antibodysociety.org/antibodies<br>-<br>in<br>-<br>late<br>-<br>stage<br>-<br>clinical<br>-<br>studies/ | |
| --- | ||
| Substantial and Sustained Early<br>-<br>Stage ADC<br>Partnering Activity<br>17<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br> →<br>New ADC platforms are improving clinical outcomes of ADC products, leading to several recent approvals<br> →<br>Large recent investments in ADC platforms expected to increase the demand for novel targets<br> →<br>Ectopically expressed targets represent a unique ADC target class<br>Merck<br>-<br>Kelun<br>Preclinical (7 ADCs)<br>Up to ~$9.5B<br>2022<br>Seagen<br>-<br>RemeGen<br>Phase 2<br>Up to ~$2.6B<br>2021<br>BMS<br>-<br>Eisai<br>Phase 1<br>Up to $3.1B<br>2021<br>Merck<br>-<br>Velos<br>Phase 1/2<br>$2.8B<br>2020<br>AZN<br>-<br>Daiichi Sankyo<br>Phase 1<br>Up to $6B<br>2020<br>BI<br>-<br>NBE<br>Phase 1<br>$1.5B<br>2020<br>Preclinical Stage Deals<br>1<br>GSK<br>-<br>Mersana<br>Preclinical<br>Up to ~$1.3B<br>2022<br>1.<br>www.cortellis.com | ||
| --- | ||
| Oncology Lead Program<br>IMM<br>-<br>ONC<br>-<br>01<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved. | ||
| --- | ||
| Anti<br>-<br>IL<br>-<br>38 in Oncology<br>Selective Immuno<br>-<br>oncology Therapy, IND Filing Anticipated Mid<br>-<br>2023<br>19<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>CPIs effective, but response rate is limited<br>Cytokine<br>-<br>targeted therapies limited by inappropriate<br>TME context, off<br>-<br>target effects, poor efficacy<br>Anti<br>-<br>IL<br>-<br>38 therapy may overcome several limitations<br> →<br>IL<br>-<br>38 primarily expressed in epithelial tissues, frequent<br>tumor source (carcinomas, adenomas)<br> →<br>IL<br>-<br>38 effects are context<br>-<br>dependent, based upon cell<br>pathology and inflammatory status<br> →<br>Anti<br>-<br>IL<br>-<br>38 reactivates key immune antitumor pathways<br>Potential indications include<br>squamous cell carcinomas, such as head & neck, gastroesophageal and lung<br>IgG1 IL<br>-<br>38 neutralizing antibody<br>expected to:<br> →<br>Promote activated immunocyte<br>tumor infiltration<br> →<br>Enhance innate and adaptive<br>immune antitumor response<br> →<br>Extend treatment response from<br>hours to weeks<br> →<br>Benefit a significant proportion of<br>patients treated | ||
| --- | ||
| IL<br>-<br>38 is Expressed in Multiple Tumors<br>2<br>IHC Data Supports Transcriptional Data<br>3<br> →<br>Tumor Versus Healthy Adjacent Tissue Expression<br>(% of Patient Expression)<br> →<br>Pathology Scoring of Individual Head & Neck Cancer Patient<br>Samples by Stage<br>IL<br>-<br>38 Expression in Solid Tumors<br>20<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>D<br>o<br>c<br>0<br>3<br>1<br>4<br>4<br>4<br>R<br>n<br>s<br>0<br>5<br>0<br>2<br>6<br>8<br>D<br>o<br>c<br>1<br>8<br>0<br>3<br>7<br>0<br>D<br>o<br>c<br>1<br>6<br>0<br>1<br>1<br>8<br>D<br>o<br>c<br>1<br>7<br>0<br>3<br>0<br>8<br>R<br>l<br>a<br>1<br>5<br>0<br>0<br>7<br>6<br>R<br>l<br>a<br>0<br>6<br>0<br>0<br>7<br>7<br>R<br>l<br>a<br>0<br>2<br>0<br>0<br>5<br>4<br>R<br>l<br>a<br>0<br>9<br>0<br>0<br>3<br>7<br>R<br>l<br>a<br>1<br>1<br>0<br>0<br>2<br>6<br>R<br>l<br>a<br>1<br>3<br>0<br>0<br>4<br>2<br>R<br>l<br>a<br>1<br>3<br>0<br>0<br>3<br>0<br>R<br>l<br>a<br>1<br>4<br>0<br>0<br>6<br>5<br>R<br>l<br>a<br>0<br>1<br>0<br>0<br>8<br>8<br>D<br>o<br>c<br>0<br>9<br>0<br>2<br>4<br>7<br>D<br>o<br>c<br>0<br>6<br>2<br>3<br>0<br>2<br>D<br>o<br>c<br>0<br>6<br>2<br>2<br>3<br>8<br>D<br>o<br>c<br>0<br>6<br>2<br>3<br>0<br>7<br>D<br>o<br>c<br>0<br>3<br>0<br>4<br>6<br>3<br>D<br>o<br>c<br>1<br>3<br>0<br>4<br>7<br>2<br>D<br>o<br>c<br>1<br>3<br>0<br>4<br>9<br>8<br>D<br>o<br>c<br>1<br>1<br>0<br>1<br>9<br>3<br>D<br>o<br>c<br>0<br>2<br>2<br>7<br>8<br>2<br>D<br>o<br>c<br>1<br>4<br>0<br>0<br>7<br>3<br>D<br>o<br>c<br>1<br>4<br>0<br>1<br>4<br>8<br>D<br>o<br>c<br>0<br>6<br>2<br>3<br>0<br>5<br>D<br>o<br>c<br>0<br>9<br>0<br>1<br>4<br>9<br>D<br>o<br>c<br>0<br>7<br>0<br>3<br>6<br>9<br>D<br>o<br>c<br>1<br>4<br>0<br>0<br>4<br>5<br>D<br>o<br>c<br>1<br>0<br>0<br>3<br>0<br>8<br>D<br>o<br>c<br>1<br>8<br>0<br>0<br>7<br>4<br>R<br>l<br>a<br>0<br>1<br>0<br>1<br>6<br>2<br>R<br>l<br>a<br>1<br>3<br>0<br>0<br>5<br>8<br>R<br>l<br>a<br>0<br>1<br>0<br>1<br>7<br>3<br>R<br>l<br>a<br>1<br>3<br>0<br>0<br>6<br>5<br>R<br>l<br>a<br>0<br>2<br>0<br>0<br>6<br>3<br>R<br>l<br>a<br>0<br>5<br>0<br>0<br>0<br>7<br>R<br>l<br>a<br>0<br>2<br>0<br>0<br>5<br>8<br>D<br>o<br>c<br>0<br>6<br>1<br>8<br>3<br>0<br>D<br>o<br>c<br>0<br>6<br>0<br>6<br>2<br>1<br>R<br>n<br>s<br>0<br>2<br>0<br>6<br>6<br>6<br>D<br>o<br>c<br>1<br>4<br>0<br>1<br>8<br>5<br>D<br>o<br>c<br>0<br>3<br>1<br>8<br>0<br>8<br>D<br>o<br>c<br>0<br>7<br>0<br>3<br>1<br>0<br>D<br>o<br>c<br>1<br>4<br>0<br>0<br>5<br>2<br>D<br>o<br>c<br>1<br>8<br>0<br>3<br>6<br>5<br>D<br>o<br>c<br>1<br>6<br>0<br>0<br>7<br>7<br>D<br>o<br>c<br>0<br>3<br>0<br>4<br>5<br>6<br>D<br>o<br>c<br>0<br>6<br>2<br>2<br>9<br>8<br>R<br>l<br>a<br>0<br>1<br>0<br>0<br>0<br>5<br>R<br>l<br>a<br>1<br>0<br>0<br>0<br>1<br>8<br>R<br>l<br>a<br>1<br>0<br>0<br>0<br>1<br>0<br>R<br>l<br>a<br>1<br>5<br>0<br>0<br>9<br>8<br>R<br>l<br>a<br>0<br>1<br>0<br>0<br>5<br>9<br>R<br>l<br>a<br>0<br>2<br>0<br>0<br>5<br>3<br>R<br>l<br>a<br>0<br>1<br>0<br>1<br>0<br>7<br>R<br>l<br>a<br>1<br>5<br>0<br>0<br>9<br>2<br>R<br>l<br>a<br>0<br>1<br>0<br>1<br>0<br>9<br>R<br>l<br>a<br>0<br>1<br>0<br>1<br>0<br>6<br>R<br>l<br>a<br>0<br>5<br>0<br>2<br>7<br>2<br>R<br>l<br>a<br>0<br>1<br>0<br>1<br>4<br>5<br>R<br>l<br>a<br>0<br>6<br>0<br>0<br>2<br>4<br>R<br>l<br>a<br>0<br>1<br>0<br>0<br>7<br>2<br>R<br>l<br>a<br>0<br>2<br>0<br>2<br>5<br>8<br>R<br>l<br>a<br>0<br>1<br>0<br>1<br>4<br>4<br>R<br>l<br>a<br>0<br>6<br>0<br>0<br>8<br>8<br>R<br>l<br>a<br>0<br>2<br>0<br>0<br>6<br>0<br>R<br>l<br>a<br>0<br>6<br>0<br>5<br>9<br>6<br>D<br>o<br>c<br>1<br>4<br>0<br>1<br>2<br>4<br>D<br>o<br>c<br>1<br>8<br>0<br>2<br>6<br>8<br>0<br>2<br>4<br>6<br>Stage I<br>Stage II<br>Stage III<br>Stage IV<br>A<br>Weak<br>Moderate<br>Strong<br>Negative<br>SCC of Max. Sinus<br>Stage III. T3N0M0<br>SCC of Tongue root<br>Stage II. T2N0M0<br>ACC of Parotid<br>Stage II. T2N0M0<br>Isotype<br>Control<br>Anti IL<br>-<br>38<br>(Immunome Clone)<br>Weak<br>Moderate<br>Strong<br>Head & Neck<br>Lung, Squamous<br>Esophagus<br>Cervix<br>Skin<br>Lung, Adeno<br>23%<br>53%<br>41%<br>48%<br>25%<br>14%<br>30%<br>9%<br>Bladder<br>Prostate<br>log2TPM<br>log2TPM<br>1.<br>Source: Tempus Real<br>-<br>World Data<br>2.<br>Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset<br>3.<br>Immunome Internal Data<br>IL<br>-<br>38 Expression Confirmed in Multiple Tumors of High Unmet Medical Need<br>1 | ||
| --- | ||
| IL<br>-<br>38 Overexpression Inhibits Infiltration<br>of T cells into Tumors<br>In Vivo<br>High IL<br>-<br>38 Expression is Associated with Reduced<br>Immune Cell Infiltration*<br> →<br>IL<br>-<br>38 high tumor samples correlate with reduced infiltration of<br>multiple immune subsets, especially in lung, head & neck, and<br>gastroesophageal cancers<br>IL<br>-<br>38 Expression is Associated with Reduced Immune Cell Infiltration<br>21<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>*Immunome analysis of the Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset<br>Similar findings were also confirmed in real<br>-<br>world data (Tempus)<br>-<br>0<br>..<br>6<br>-<br>0<br>..<br>4<br>-<br>0<br>..<br>2<br>0<br>..<br>0<br>0<br>..<br>2<br>0<br>..<br>4<br>0<br>..<br>6<br>SK<br>C<br>M<br>C<br>ESC<br>LUAD<br>ESC<br>A<br>L<br>U<br>SC<br>H<br>N<br>SC<br>T Cells<br>-<br>0<br>..<br>3<br>-<br>0<br>..<br>2<br>-<br>0<br>..<br>1<br>0<br>..<br>0<br>0<br>..<br>1<br>0<br>..<br>2<br>0<br>..<br>3<br>SK<br>C<br>M<br>C<br>ESC<br>LUAD<br>ESC<br>A<br>L<br>U<br>SC<br>H<br>N<br>SC<br>B Cells<br>-<br>0<br>..<br>6<br>-<br>0<br>..<br>4<br>-<br>0<br>..<br>2<br>0<br>..<br>0<br>0<br>..<br>2<br>0<br>..<br>4<br>0<br>..<br>6<br>SK<br>C<br>M<br>C<br>ESC<br>LUAD<br>ESC<br>A<br>L<br>U<br>SC<br>H<br>N<br>SC<br>Macrophages<br>-<br>0<br>..<br>5<br>0<br>-<br>0<br>..<br>2<br>5<br>0<br>..<br>0<br>0<br>0<br>..<br>2<br>5<br>0<br>..<br>5<br>0<br>SK<br>C<br>M<br>C<br>ESC<br>LUAD<br>ESC<br>A<br>L<br>U<br>SC<br>H<br>N<br>SC<br>Monocytes<br>-<br>0<br>..<br>2<br>-<br>0<br>..<br>1<br>0<br>..<br>0<br>0<br>..<br>1<br>0<br>..<br>2<br>SK<br>C<br>M<br>C<br>ESC<br>LUAD<br>ESC<br>A<br>L<br>U<br>SC<br>H<br>N<br>SC<br>NK Cells<br>SK<br>C<br>M<br>C<br>ESC<br>LUAD<br>ESC<br>A<br>L<br>U<br>SC<br>H<br>N<br>SC<br>Key<br>D<br>e<br>c<br>r<br>e<br>a<br>s<br>e<br>d<br><br>i<br>n<br><br>I<br>L<br>-<br>3<br>8<br><br>H<br>i<br>g<br>h<br><br>T<br>u<br>m<br>o<br>r<br>s<br>I<br>n<br>c<br>r<br>e<br>a<br>s<br>e<br>d<br><br>i<br>n<br><br>I<br>L<br>-<br>3<br>8<br><br>H<br>i<br>g<br>h<br><br>T<br>u<br>m<br>o<br>r<br>s<br>ImSig Score Dif<br>ference (IL-38 High minus IL-38 low)<br>Kinoshita et al, Cancer Immunol.<br>Immunother<br>..(2021) 70:123<br>1200<br>1000<br>800<br>600<br>400<br>200<br>CD3 (/mm<br>2<br>)<br>LLC<br>-<br>vector<br>LLC<br> –<br>IL38<br>800<br>700<br>600<br>500<br>400<br>300<br>200<br>100<br>0<br>CD8 (/mm<br>2<br>)<br>LLC<br>-<br>vector<br>LLC<br> –<br>IL38 | ||
| --- | ||
| IMM<br>-<br>ONC<br>-<br>01 Anti IL<br>-<br>38 Antibody<br>Blocking IL<br>-<br>38<br>Leads to Tumor Control in Two Different Tumor Models<br>1<br>22<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Demonstration of Anti<br>-<br>Tumor Activity<br>(B16.F10 Model)<br>Induction of Anti<br>-<br>Tumor Memory<br>(EMT6 Model)<br> →<br>Immunologically cold tumor model<br> →<br>IMM<br>-<br>ONC<br>-<br>01 significantly inhibits B16.F10 tumor growth<br>in vivo<br>at 10 and 50 mg/kg doses<br> →<br>~40% response rate upon treatment with IMM<br>-<br>ONC<br>-<br>01<br> →<br>Animals with complete cures resistant to tumor<br>re<br>-<br>challenge<br> –<br>Strongly suggests immunological memory<br> –<br>Consistent with indirect effect on T cells<br>0<br>1<br>0<br>2<br>0<br>3<br>0<br>4<br>0<br>0<br>5<br>0<br>1<br>0<br>0<br>D<br>a<br>y<br>%<br><br>S<br>u<br>r<br>v<br>i<br>v<br>a<br>l<br>I<br>M<br>M<br>-<br>O<br>N<br>C<br>-<br>0<br>1<br>V<br>e<br>h<br>i<br>c<br>l<br>e<br><br>c<br>o<br>n<br>t<br>r<br>o<br>l<br>5<br>1<br>0<br>1<br>5<br>2<br>0<br>2<br>5<br>0<br>2<br>5<br>0<br>5<br>0<br>0<br>7<br>5<br>0<br>1<br>0<br>0<br>0<br>D<br>a<br>y<br>T<br>u<br>m<br>o<br>r<br><br>V<br>o<br>l<br>u<br>m<br>e<br>M<br>e<br>a<br>n<br> ±<br><br>S<br>E<br>M<br><br>(<br>m<br>m<br>3<br>)<br>V<br>e<br>h<br>i<br>c<br>l<br>e<br><br>c<br>o<br>n<br>t<br>r<br>o<br>l<br>I<br>M<br>M<br>-<br>O<br>N<br>C<br>-<br>0<br>1<br>1. AACR<br>-<br>NCI<br>-<br>EORTC Molecular Targets & Cancer Therapeutics Meeting, October<br>2021 (<br>https://doi.org/10.1158/1535<br>-<br>7163.TARG<br>-<br>21<br>-<br>LBA022<br>)<br>Isotype IMM<br>-<br>ONC<br>-<br>01<br>50 10 50 mg/Kg Q3D<br>*<br>p<br> < 0.05 | ||
| --- | ||
| →<br>In vitro<br>and<br>in vivo<br>preclinical research confirms<br>antitumor<br>activity of IMM<br>-<br>ONC<br>-<br>01 in solid tumors as a<br>monotherapy<br> →<br>Gene expression profiling of patient tumors suggest<br>normal<br>IL<br>-<br>38 biology is co<br>-<br>opted by tumors of squamous<br>origin to<br>suppress immune infiltration<br> →<br>IMM<br>-<br>ONC<br>-<br>01 exhibits favorable pharmacokinetic<br>profile<br> →<br>IMM<br>-<br>ONC<br>-<br>01 is well tolerated in GLP toxicology studies<br> →<br>Potential indications include squamous cell<br>carcinomas,<br>such as<br>head & neck, gastroesophageal<br>and lung<br>IND Submission Anticipated in Mid<br>-<br>2023<br>23<br>IMM<br>-<br>ONC<br>-<br>01 Program Summary<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Takeda<br>et al.<br>PLoS<br>One<br>(2017) | ||
| --- | ||
| 24<br>Financial Overview and Intellectual Property Snapshot<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br> →<br>Cash at least through 3Q 2024<br> →<br>Eligible for additional platform access and option payments during the research term in the AbbVie Collaboration<br> →<br>Platform enables flexible business model<br> –<br>partnerships and proprietary programs<br>Active ongoing research will generate additional IP, including trade secrets and patent<br>applications around platform and pipeline<br>Antibodies for lead oncology programs and uses thereof covered by international patent<br>applications; projected expirations in 2039 and beyond<br>Platform technology and discovery engine protected through base patents and know<br>-<br>how<br>exclusively<br>-<br>licensed by Immunome and further patents and trade secrets owned by Immunome | ||
| --- | ||
| Immunome “At a Glance”<br>Disruptive<br>Platform<br>Leveraging Human Immune Response<br>25<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Discovery Of Novel<br>Antibody<br>-<br>Target Pairs<br> →<br>Enabled by patient memory B cell interrogation<br> →<br>Widely applicable across therapeutic areas<br> →<br>Platform uniquely suited to rapidly identify novel Antibody<br>-<br>Drug Conjugate (ADC) targets<br>Capital<br>-<br>Efficient<br>Business Strategy<br> →<br>Strong cash position; runway through at least 3Q 2024<br> →<br>Value creation through partnerships and proprietary programs<br>Validating<br>Collaborations<br> →<br>AbbVie collaboration<br>$30M upfront and up to ~$2.8B in total<br> →<br>$17.6M funding from U.S. DoD JPEO<br>-<br>CBRND in collaboration with DHA<br>Lead program,<br>Anti IL<br>-<br>38 Antibody<br>IND Submission Mid<br>-<br>2023<br> →<br>IL<br>-<br>38: A novel context dependent immune modulator in multiple solid tumors with poor prognosis<br> →<br>Potential indications: squamous carcinomas of head & neck, gastroesophageal and lung<br>Deep Research<br>Pipeline<br> →<br>Antibody targeting EPN1: Ectopically expressed, may allow for tumor specific targeting<br> →<br>Multiple additional novel targets enabling next<br>-<br>generation modalities (ADCs, T cell engagers) | ||
| --- | ||
| Matthew Robinson, PhD<br>Chief Technology Officer<br>Antibody Structure Function Expert<br>formerly at Fox Chase Cancer Center<br>26<br>Experienced Management Team<br>Purnanand<br>Sarma<br>, PhD<br>President & CEO<br>Corleen<br>Roche<br>Chief Financial Officer<br>Dennis<br>Giesing<br>, PhD<br>Chief Development Officer<br>Former CEO of Taris Biomedical<br>Sold to Johnson & Johnson in 2019<br>Former US CFO, Biogen<br>Former CFO, Global Vaccines, Wyeth/Pfizer<br>Former CSO at Taris Biomedical<br>Led BARDA funded pandemic flu<br>program at<br>MediVector<br>Sandra Stoneman, Esq.<br>Chief Legal Officer<br>Former Partner at Duane Morris<br>Life Sciences practice group leader<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Mike Morin, PhD<br>Chief Scientist<br>Oversaw cancer, immunology and<br>anti<br>-<br>bacterial drug discovery at Pfizer | ||
| --- | ||
| 27<br>Board of Directors<br>Copyright © 2023 Immunome, Inc.<br>All rights reserved.<br>Michael Rapp<br>Chairman of the Board<br>John<br>LaMattina<br>, PhD<br>Franklyn G. Prendergast, MD<br>Michael<br>Lefenfeld<br>Philip<br>Wagenheim<br>Managing Member,<br>Broadband Capital Investments, LLC<br>Formerly President,<br>Pfizer Global Research & Development<br>President and CEO, Hexion, Inc.<br>Former President and CEO,<br>Cyanco<br>Co<br>-<br>founder of<br>SiGNa<br>Chemistry<br>Managing Partner,<br>Broadband Capital Partners, LLC<br>Purnanand<br>Sarma<br>, PhD<br>President & CEO, Immunome<br>Former CEO of Taris Biomedical<br>Sold to Johnson & Johnson in 2019<br>Former charter Director of the Mayo Center for Individualized Medicine<br>Former member of the Mayo Board of Governors<br>Former member of the Mayo Foundation’s Board of Trustees<br>Former Director of the Mayo Clinic Comprehensive Cancer Center<br>Former non<br>-<br>executive member of the Board of Directors, Eli Lilly<br>Richard Baron<br>Former VP and CFO,<br>Zynerba<br>Pharmaceuticals, Inc.<br>Former SVP and CFO, Globus Medical<br>Former CFO, various biotech, managed care and generics companies | ||
| --- |